Research statistics
Cagrilintide research: publications and trials
At a glance
Publications, all years
97
Since 1986
Publications in 2026 so far
39
Through November 15, 2026
Human clinical research
20.0%
19 of 95 classified
Registered clinical trials
41
ClinicalTrials.gov
Randomized controlled trials
15
Publications reporting an RCT in people
Systematic reviews and meta-analyses
13
Preclinical studies
25.3%
12 animal · 11 in vitro · 1 computational
Records that only mention it
31
Not counted above
Status in the library: In clinical trials. Groups: Amylin analogues. 2 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Cagrilintide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 1986 | 0 | 2 | 0 | 0 | 2 |
| 1987 | 1 | 4 | 0 | 1 | 6 |
| 1988 | 0 | 1 | 0 | 0 | 1 |
| 1990 | 1 | 0 | 0 | 0 | 1 |
| 1994 | 1 | 0 | 0 | 0 | 1 |
| 1995 | 0 | 1 | 0 | 0 | 1 |
| 2021 | 2 | 1 | 2 | 2 | 7 |
| 2022 | 0 | 1 | 2 | 0 | 3 |
| 2023 | 1 | 0 | 3 | 0 | 4 |
| 2024 | 1 | 1 | 8 | 0 | 10 |
| 2025 | 3 | 6 | 6 | 7 | 22 |
| 2026 (to date) | 9 | 7 | 20 | 3 | 39 |
Study types
| Review | 28 |
|---|---|
| Randomized controlled trial | 15 |
| Animal study | 12 |
| In vitro study | 11 |
| Editorial, letter or other | 11 |
| Meta-analysis | 9 |
| Other clinical trial | 4 |
| Systematic review | 4 |
| Not yet classified | 2 |
| Computational study | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 56 |
|---|---|
| Obesity and weight management | 49 |
| Endocrinology | 25 |
| Antimicrobial and infectious disease | 12 |
| Cardiovascular | 8 |
| Gastrointestinal | 7 |
| Neurological and mental health | 4 |
| Musculoskeletal | 3 |
| Reproductive and sexual health | 2 |
| Oncology | 1 |
Registered clinical trials
7 of 14 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 24 · Recruiting: 9 · Active, not recruiting: 7 · Not yet recruiting: 1
Phase 1: 17 · Phase 2: 4 · Phase 3: 20
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times
PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses
- CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.
Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access
PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses
- Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
Diabetes, metabolic syndrome and obesity : targets and therapy · September 15, 2026 · Meta-analysis · cited 0 times · open access
PMID 42763732 · DOI 10.2147/dmso.s616418 · Reviews and meta-analyses
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access
PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
Annals of medicine and surgery (2012) · July 13, 2026 · Meta-analysis · cited 0 times · open access
PMID 42583410 · DOI 10.1097/ms9.0000000000005353 · Reviews and meta-analyses
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
Endocrinology, diabetes & metabolism · July 1, 2026 · Meta-analysis · cited 2 times · open access
PMID 42207966 · DOI 10.1002/edm2.70248 · Reviews and meta-analyses
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
Diabetes, obesity & metabolism · March 16, 2026 · Meta-analysis · cited 5 times
PMID 41834765 · DOI 10.1111/dom.70667 · Reviews and meta-analyses
- CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
The American journal of cardiology · February 26, 2026 · Meta-analysis · cited 1 times
PMID 41759565 · DOI 10.1016/j.amjcard.2026.02.030 · Reviews and meta-analyses
- Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
Obesity (Silver Spring, Md.) · November 4, 2025 · Meta-analysis · cited 2 times · open access
PMID 41189318 · DOI 10.1002/oby.70054 · Reviews and meta-analyses
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times
PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet (London, England) · June 23, 2023 · Randomized controlled trial · cited 330 times · open access
PMID 37364590 · DOI 10.1016/s0140-6736(23)01163-7 · Human clinical research
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Lancet (London, England) · April 22, 2021 · Randomized controlled trial · cited 315 times
PMID 33894838 · DOI 10.1016/s0140-6736(21)00845-x · Human clinical research
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lancet (London, England) · November 16, 2021 · Randomized controlled trial · cited 273 times · open access
PMID 34798060 · DOI 10.1016/s0140-6736(21)01751-7 · Human clinical research
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine · June 22, 2025 · Randomized controlled trial · cited 233 times
PMID 40544433 · DOI 10.1056/nejmoa2502081 · Human clinical research
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
The New England journal of medicine · June 22, 2025 · Randomized controlled trial · cited 140 times
PMID 40544432 · DOI 10.1056/nejmoa2502082 · Human clinical research
Latest publications
- Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.
The lancet. Diabetes & endocrinology · November 14, 2026 · Not yet classified · cited 0 times
PMID 43033821 · DOI 10.1016/s2213-8587(26)00275-5 · Not yet classified
- Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.
Molecular metabolism · October 28, 2026 · Animal study · cited 0 times
PMID 42951207 · DOI 10.1016/j.molmet.2026.102464 · Animal studies
- Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times
PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses
- Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).
American heart journal · October 6, 2026 · Other clinical trial · cited 0 times · open access
PMID 42838477 · DOI 10.1016/j.ahj.2026.107626 · Human clinical research
- CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.
Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access
PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses
- Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · October 1, 2026 · Review · cited 0 times · open access
PMID 42808923 · DOI 10.1002/ncp.70180 · Reviews and meta-analyses
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Diabetes therapy : research, treatment and education of diabetes and related disorders · September 28, 2026 · Review · cited 0 times · open access
PMID 42803913 · DOI 10.1007/s13300-026-01921-0 · Reviews and meta-analyses
- Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Nature metabolism · September 15, 2026 · Animal study · cited 0 times · open access
PMID 42744908 · DOI 10.1038/s42255-026-01603-y · Animal studies
- Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
Diabetes, metabolic syndrome and obesity : targets and therapy · September 15, 2026 · Meta-analysis · cited 0 times · open access
PMID 42763732 · DOI 10.2147/dmso.s616418 · Reviews and meta-analyses
- Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.
Diabetes, metabolic syndrome and obesity : targets and therapy · September 2, 2026 · Review · cited 0 times · open access
PMID 42812898 · DOI 10.2147/dmso.s626279 · Reviews and meta-analyses
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: AM833; Cagrilintide; NN9838
((TITLE_ABS:"AM833" OR CHEM:"AM833" OR TITLE_ABS:"AM 833" OR CHEM:"AM 833") OR (TITLE_ABS:"Cagrilintide" OR CHEM:"Cagrilintide") OR (TITLE_ABS:"NN9838" OR CHEM:"NN9838" OR TITLE_ABS:"NN 9838" OR CHEM:"NN 9838")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Cagrilintide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/cagrilintide